Cigna Corporation (NYSE: CI) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 11.51 | EPS (ttm) | 24.16 | Insider Own | 0.35% | Shs Outstand | 264.24M | Perf Week | -1.73% |
| Market Cap | 73.50B | Forward P/E | 8.31 | EPS next Y | 33.48 | Insider Trans | -24.25% | Shs Float | 262.88M | Perf Month | -0.08% |
| Enterprise Value | 99.08B | PEG | 1.04 | EPS next Q | 7.46 | Inst Own | 88.34% | Short Float | 1.99% | Perf Quarter | -5.71% |
| Income | 6.42B | P/S | 0.26 | EPS this Y | 26.24% | Inst Trans | 0.08% | Short Ratio | 3.04 | Perf Half Y | 5.99% |
| Sales | 282.38B | P/B | 1.71 | EPS next Y | 9.78% | ROA | 4.08% | Short Interest | 5.24M | Perf YTD | 1.07% |
| Book/sh | 162.39 | P/C | 11.67 | EPS next 5Y | 11.03% | ROE | 15.24% | 52W High | 315.46 -11.82% | Perf Year | -7.55% |
| Cash/sh | 23.83 | P/FCF | 8.19 | EPS past 3/5Y | 1.17% -0.70% | ROIC | 7.69% | 52W Low | 239.51 16.14% | Perf 3Y | 0.54% |
| Dividend Est. | 6.24 (2.24%) | EV/EBITDA | 8.42 | Sales past 3/5Y | 15.06% 11.38% | Gross Margin | 11.66% | Volatility | 2.06% 1.89% | Perf 5Y | 31.43% |
| Dividend TTM | 6.19 (2.23%) | EV/Sales | 0.35 | EPS Y/Y TTM | 99.34% | Oper. Margin | 3.46% | ATR (14) | 6.62 | Perf 10Y | 116.49% |
| Dividend Ex-Date | Sep 08, 2026 | Quick Ratio | 0.74 | Sales Y/Y TTM | 14.27% | Profit Margin | 2.27% | RSI (14) | 47.55 | Recom | 2.28 |
| Dividend Gr. 3/5Y | 10.47% 172.77% | Current Ratio | 0.85 | EPS Q/Q | 8.06% | SMA20 | -0.35% | Beta | 0.29 | Target Price | 338.33 |
| Payout | 25.31% | Debt/Eq | 0.75 | Sales Q/Q | 6.60% | SMA50 | -1.81% | Rel Volume | 0.93 | Prev Close | 275.83 |
| Employees | 66,685 | LT Debt/Eq | 0.74 | Earnings | Oct 29 | SMA200 | -0.52% | Avg Volume | 1.66M | Price | 278.17 |
| IPO Date | Mar 31, 1982 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.42% 2.17% | Net Debt/EBITDA | 2.17 | Volume | 1,542,767 | Change | 0.85% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-04-26 | Downgrade | Jefferies | Buy → Hold | $330 → $307 |
| Aug-03-26 | Downgrade | Raymond James | Strong Buy → Outperform | $340 → $320 |
| Jul-31-26 | Reiterated | Robert W. Baird | $337 → $362 | |
| Jul-31-26 | Reiterated | Wells Fargo | Equal Weight | $300 → $307 |
| Jul-31-26 | Reiterated | Guggenheim | Buy | $318 → $361 |
| Jun-16-26 | Reiterated | Wolfe Research | $294 → $315 | |
| Jun-08-26 | Reiterated | Mizuho | Outperform | $330 → $340 |
| May-26-26 | Downgrade | Barclays | Overweight → Equal Weight | $310 → $304 |
| May-22-26 | Reiterated | UBS | Buy | $375 → $400 |
| May-20-26 | Reiterated | Morgan Stanley | Overweight | $355 → $361 |
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers. Meanwhile, the Cigna Healthcare segment delivers an extensive portfolio of products and services, encompassing medical, pharmaceutical, behavioral health, dental, vision, and health advocacy programs for both insured and self-insured customers. This segment also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans specifically for seniors, in addition to individual health insurance options available on and off public exchanges. Globally, Cigna Healthcare extends international health coverage and benefits to mobile professionals and employees of multinational organizations. Furthermore, the company issues permanent insurance contracts to corporations, designed to cover the lives of specific employees for funding future benefit obligations. Cigna distributes its various offerings through insurance brokers and consultants, direct sales channels to employers, unions, and individuals, and via both private and public exchanges.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 282,382 | 274,952 | 247,121 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 249,453 | 248,966 | 221,157 | — | — | — | — | — | — | |
| Gross Profit | 32,929 | 25,986 | 25,964 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13,960 | 14,000 | 14,569 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 9,209 | 2,857 | 1,978 | — | — | — | — | — | — | |
| Operating Income | 9,760 | 9,129 | 9,417 | — | — | — | — | — | — | |
| Interest Expense | 1,395 | 1,381 | 1,435 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 86 | -155 | -2,713 | — | — | — | — | — | — | |
| Net Income Before Taxes | 8,451 | 7,593 | 5,269 | — | — | — | — | — | — | |
| Income Taxes | 1,508 | 1,345 | 1,491 | — | — | — | — | — | — | |
| Consolidated Net Income | 6,416 | 5,957 | 3,434 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 6,943 | 6,248 | 3,778 | — | — | — | — | — | — | |
| Net Income | 6,416 | 5,957 | 3,434 | — | — | — | — | — | — | |
| EPS (Recurring) | 24.25 | 22.30 | 12.25 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 24.25 | 22.30 | 12.25 | — | — | — | — | — | — | |
| EPS (Diluted) | 24.16 | 22.17 | 12.12 | — | — | — | — | — | — | |
| EBITDA | 11,773 | 11,607 | 11,446 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 11.51 | 12.41 | 22.78 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.26 | 0.27 | 0.31 | — | — | — | — | — | — | |
| Gross Margin | 11.66 | 9.45 | 10.51 | — | — | — | — | — | — | |
| Operating Margin | 3.46 | 3.32 | 3.81 | — | — | — | — | — | — | |
| Net Margin | 2.27 | 2.17 | 1.39 | — | — | — | — | — | — | |
| Shares Outstanding | 264 | 266 | 280 | — | — | — | — | — | — | |
| Market Capitalization | 73,437 | 73,211 | 77,319 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Neville Everett | See Remarks | Sep 03 '26 | Sale | 284.05 | 617 | 175,259 | 5,053 | Sep 08 |
| Jones Nicole S | See Remarks | Aug 18 '26 | Sale | 279.61 | 2,677 | 748,516 | 25,880 | Aug 20 |
| Jones Nicole S | See Remarks | Aug 05 '26 | Option Exercise | 192.02 | 1,301 | 249,818 | 28,557 | Aug 06 |
| Jones Nicole S | See Remarks | Aug 04 '26 | Sale | 276.27 | 19,436 | 5,369,584 | 27,256 | Aug 06 |
| Jones Nicole S | See Remarks | Aug 04 '26 | Option Exercise | 192.02 | 14,045 | 2,696,921 | 46,692 | Aug 06 |
| Kates Jamie G | Chief Accounting Officer | Jun 12 '26 | Option Exercise | 152.89 | 899 | 137,452 | 3,267 | Jun 16 |
| Kates Jamie G | Chief Accounting Officer | Jun 12 '26 | Sale | 298.61 | 899 | 268,452 | 2,368 | Jun 16 |
| Cordani David | Chairman & CEO | May 13 '26 | Option Exercise | 165.54 | 23,429 | 3,878,406 | 57,766 | May 14 |
| Cordani David | Chairman & CEO | May 12 '26 | Sale | 292.82 | 201,878 | 59,114,187 | 34,337 | May 14 |
| Cordani David | Chairman & CEO | May 12 '26 | Option Exercise | 170.94 | 189,114 | 32,326,815 | 236,215 | May 14 |
| Jones Nicole S | See Remarks | Mar 02 '26 | Sale | 288.91 | 2,307 | 666,515 | 32,647 | Mar 03 |
| Neville Everett | See Remarks | Mar 02 '26 | Sale | 288.91 | 1,719 | 496,636 | 5,670 | Mar 03 |
| Cordani David | Chairman & CEO | Nov 03 '25 | Buy | 241.88 | 4,134 | 999,916 | 157,935 | Nov 03 |
| Evanko Brian C | See Remarks | Oct 06 '25 | Option Exercise | 139.22 | 901 | 125,437 | 52,083 | Oct 07 |
| Evanko Brian C | See Remarks | Oct 03 '25 | Sale | 300.00 | 5,368 | 1,610,400 | 51,182 | Oct 07 |